Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn’s disease: Phenotype-genotype correlations

Table 7 Clinical characteristics of CD patients, with respect to the presence or absence of NOD2/CARD15 mutations.

		Total (n = 527)	Non carrier (n = 342)	Carrier (n = 185)	1 allele (n = 133)	2 alleles (n = 52)
Male/Female		265/262	174/168	91/94	71/62	20/32
Age (yr)		36.9±9.1	37.9±13.0	34.9±11.61	35.2±11.7	34.3±11.4
Age at presentation (yr)		37.1±7.6	29.8±12.1	26.4±9.71	26.4±9.6	26.5±10.2
Duration (yr)		8.2±5.0	8.1±7.0	8.5±6.7	8.8±7.0	7.9±5.8
Familiar IBD n (%)		63 (11.9)	38 (11.1)	25 (13.5)	17 (12.8)	8 (15.4)
Location (n)	L1	136	84	521	362	162
	L2	136	103	33	26	7
	L3	251	152	99	71	28
	L4	4	3	1	0	1
Behavior (n)	B1	216	151	651	483	17
	B2	128	71	57	42	15
	B3	183	120	63	43	20
Perianal disease n (%)		140 (26.6)	89 (26.0)	51 (27.6)	36 (27.1)	15 (28.9)
Frequent relapse n (%)		195 (37.1)	126 (36.9)	69 (37.3)	47 (35.3)	22 (42.3)
Extraintestinal manifestations n (%)		175 (33.2)	117 (34.2)	58 (31.3)	45 (33.8)	13 (25)
Arthritis n (%)		147 (27.9)	98 (28.7)	49 (26.5)	36 (27.1)	13 (25)
Occular n (%)		27 (5.1)	18 (5.2)	9 (4.9)	9 (6.8)	0
Erythema nodosum/Pyoderma n (%)		48 (9.1)	30 (8.8)	18 (9.7)	15 (11.3)	3 (5.8)
PSCa		18 (3.4)	15 (4.4)	3 (1.6)	3 (2.3)	0
Steroid use/		440 (83.5)/	282 (82.4)/	158 (85.4)/	114 (85.7)/	44 (84.6)/
refractory n (%)		44 (10)	28 (9.3)	16 (10.1)	10 (8.8)	6 (13.6)
Azathioprine use/		337 (64.1)/	208 (60.8)/	129 (69.7)1/	89 (66.9)/	40 (76.9)4/
refractory n (%)		19 (5.6)	10 (4.8)	9 (7.0)	7 (7.8)	2 (5)
Operation n (%)		220 (41.8)	128 (37.4)	92 (49.7)1	66 (49.6)2	26 (50.0)2
Smoking (n)	Never	308	191	117	80	37
	Active	170	115	55	42	13
	Previous	49	36	13	11	2

¹P<0.03 between carriers and non-carriers,

²P<0.03 between patients carrying one or two mutant allele and non-carriers,

³P = 0.043 between patients carrying one mutant allele and non-carriers,

⁴P = 0.025 between patients carrying two mutant allele and non-carriers.